- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.05. | Exploring AI in pharma: how can we achieve lift-off? | ||
| 23.05. | BioNTech announces £1bn UK investment to boost regional R&D presence | ||
| 23.05. | Researchers uncover promising treatment approach for inherited breast cancer | ||
| 23.05. | Clinical trials - overcoming the barriers to improved enrolment and retention | ||
| 22.05. | Regeneron to acquire human genetics company 23andMe for $256m | ||
| 22.05. | AstraZeneca shares late-stage results for Airsupra in mild asthma patients | ||
| 21.05. | Pfizer gains rights to 3SBio's investigational bispecific antibody in deal worth over $6bn | ||
| 21.05. | Merck's Welireg granted FDA approval to treat rare tumour types PPGL | ||
| 21.05. | VML appoints Philippe Huot-Louradour as director of VML Health France | ||
| 20.05. | J&J's Tremfya approved by MHRA to treat Crohn's disease and ulcerative colitis | ||
| 20.05. | FDA approves Fujirebio's Lumipulse as first Alzheimer's disease blood test | ||
| 20.05. | Alnylam shares phase 3 results for Amvuttra in rare heart disease ATTR-CM | ||
| 19.05. | AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies | ||
| 19.05. | Sanofi unveils $20bn US investment to boost R&D and manufacturing presence | ||
| 19.05. | Merck receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive | ||
| 16.05. | Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership | ||
| 16.05. | AbbVie's Emrelis granted FDA accelerated approval to treat advanced lung cancer | ||
| 16.05. | Eli Lilly to expand long-standing Purdue University partnership with $250m investment | ||
| 15.05. | GSK to acquire Boston's liver disease candidate efimosfermin in deal worth up to $2bn | ||
| 15.05. | Cytokinetics shares positive phase 3 results for aficamten in heart disease | ||
| 15.05. | Madrigal's liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis | ||
| 14.05. | Roche's Perjeta-based breast cancer regimen shows sustained survival benefits | ||
| 14.05. | Johnson & Johnson's bladder cancer therapy Balversa accepted by SMC | ||
| 14.05. | Eli Lilly's Zepbound shows superiority in head-to-head weight loss study | ||
| 13.05. | Takeda's Adzynma approved by MHRA for rare blood clotting disorder cTTP |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .